NEW YORK (GenomeWeb News) – Horizon Discovery and Novartis have struck a collaboration for cancer models that will be used in Novartis' drug research programs.

Cambridge, UK-based Horizon Discovery said this week that under the four-year strategic collaboration it will use its Genesis gene engineering platform to develop a panel of genetically defined mutant and normal (X-MAN) cancer models for the drug company. In return, Novartis will pay Horizon up-front, milestone, and renewal fees of undisclosed value.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."